The race for access: How the FAIR Act could reclaim U.S. biotech leadership

Summary

A podcast episode discusses the FAIR Act and its potential to improve U.S. patient access to rare disease clinical trials conducted abroad through accelerated, harmonized regulatory reviews. The discussion features perspectives from Aviva Strategies and PF Warriors on how the legislation could help maintain U.S. biotech competitiveness.